RxDoctor Payments Data

Brian Melton, APRN

Nurse Practitioner · Dry Ridge, KYNPI 1093251480

Payments from drug & device makers

$8,755in general payments, 2019–2025

Across 539 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • GSK$1K
  • Novo Nordisk$954
  • Lilly USA, LLC$618
  • Otsuka America Pharmaceutical, Inc.$461
  • Pfizer$402
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$8,755100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,755 in reported general payments places this provider in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$29,200
Medicare patients
160
Services billed
4,605

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban58$49,312
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$41,519
JardianceEmpagliflozin33$35,298
MounjaroTirzepatide26$34,111
FarxigaDapagliflozin Propanediol25$32,381
OzempicSemaglutide22$23,577
EntrestoSacubitril/Valsartan21$20,586
TrulicityDulaglutide12$18,162
Quetiapine Fumarate ErQuetiapine Fumarate17$17,971
JanuviaSitagliptin Phosphate21$14,053
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$11,701
Breo ElliptaFluticasone/Vilanterol11$8,618
BrilintaTicagrelor13$5,924
MyrbetriqMirabegron11$5,670
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$5,635

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$618$52,27338 claims
GSKTrelegy Ellipta, Breo Ellipta$1,019$50,13754 claims
PfizerEliquis$402$49,31258 claims
AstraZenecaFarxiga, Brilinta, Symbicort$349$43,28659 claims
Boehringer IngelheimJardiance$173$35,29833 claims
Novo NordiskOzempic$954$23,57722 claims
NovartisEntresto$119$20,58621 claims
MerckJanuvia$114$14,05321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Dry Ridge

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →